GLP1R and Parkinson disease: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as exenatide and liraglutide, have been shown in preclinical and clinical studies to restore dopaminergic neuron function, reduce neuroinflammation, and improve both motor and non-motor symptoms in PD [61,62].